注射用芦康沙妥珠单抗致癌症患者急性疼痛2例分析

doi:10.19803/j.1672-8629.20250700

中国药物警戒 ›› 2026, Vol. 23 ›› Issue (8): 934-937.
DOI: 10.19803/j.1672-8629.20250700

注射用芦康沙妥珠单抗致癌症患者急性疼痛2例分析

高朝政¹, 赵一帆¹, 苏丽^1,2, 李平^1,2,*

¹安徽中医药大学研究生院,安徽合肥 230012;
²安徽医科大学第一附属医院中西医结合肿瘤科,安徽合肥 230012

收稿日期:2025-10-09 出版日期:2026-08-15 发布日期:2026-08-17
通讯作者: ^*李平,男,博士,教授·博导,中西医结合防治肿瘤。E-mail: 1964liping@sina.com
作者简介:高朝政,男,在读硕士,中西医结合防治肿瘤。
基金资助:
安徽省高校科研项目（2022AH0511624）; 安徽省高校协同创新项目（GXXT-2023-074）; 岐黄学者安徽省种子选手培育项目（皖中医药秘〔2025〕9号）; 安徽省中医药高水平传承人才建设项目（皖中医药发展秘〔2024〕19号）; 安徽省中医药传承创新科研重点项目（2024CCCX006）

Two cases of acute systemic pain caused by sacituzumab tirumotecan for injection in cancer patients

Gao Chaozheng¹, Zhao Yifan¹, Su Li^1,2, Li Ping^1,2,*

¹Graduate School, Anhui University of Chinese Medicine, Hefei Anhui 230012, China;
²Department of Integrated Traditional Chinese and Western Medicine Oncology, the First Affiliated Hospital of Anhui Medical University, Hefei Anhui 230012, China

Received:2025-10-09 Online:2026-08-15 Published:2026-08-17

摘要/Abstract

摘要： 目的探讨注射用芦康沙妥珠单抗所致急性疼痛不良反应,评估其临床表现、机制及处理策略。方法回顾性分析2例接受该药物治疗后出现急性疼痛的癌症患者,收集其基本资料、不良反应发生时间、疼痛表现及处理措施,并结合相关文献分析可能机制。结果 2例患者均在静脉滴注后4 h内出现急性疼痛,经对症治疗及停药后症状逐渐缓解。文献提示,作为人滋养层细胞表面抗原2（TROP-2）靶向抗体偶联药物,注射用芦康沙妥珠单抗可能通过炎症介质释放或“旁观者效应”等机制诱发疼痛。结论注射用芦康沙妥珠单抗可能引发急性疼痛不良反应,临床需警惕急性重度疼痛风险,建议用药期间加强监测并及时干预。

关键词: 注射用芦康沙妥珠单抗, 抗体偶联药物, 急性疼痛, 癌症, 药品不良反应

Abstract: Objective To explore such adverse drug reactions (ADRs) as acute pain caused by sacituzumab tirumotecan for injection and to evaluate its clinical manifestations, potential mechanisms, and management strategies. Methods A retrospective analysis was conducted of two cancer patients who developed acute pain following treatment. Data on patients’ demographics, time to ADR onset, pain manifestations, and interventions was collected. Potential mechanisms were analyzed with reference to the literature. Results Both patients developed acute pain within 4 hours of intravenous infusion. Symptoms were gradually resolved after symptomatic treatment and drug discontinuation. Literature suggested that as a TROP-2-targeted antibody-drug conjugate (ADC), sacituzumab tirumotecan for injection might caused pain through such mechanisms as inflammatory mediator release or the “bystander effect”. Conclusion Sacituzumab tirumotecan for injection may cause acute pain. Clinicians should be vigilant about this risk, and close monitoring and prompt interventions during treatment are recommended.

Key words: Sacituzumab Tirumotecan for Injection, Antibody-Drug Conjugate, Acute Pain, Cancer, Adverse Drug Reaction

中图分类号:

高朝政, 赵一帆, 苏丽, 李平. 注射用芦康沙妥珠单抗致癌症患者急性疼痛2例分析[J]. 中国药物警戒, 2026, 23(8): 934-937.

Gao Chaozheng, Zhao Yifan, Su Li, Li Ping. Two cases of acute systemic pain caused by sacituzumab tirumotecan for injection in cancer patients[J]. Chinese Journal of Pharmacovigilance, 2026, 23(8): 934-937.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://zgywjj.magtechjournal.com/CN/10.19803/j.1672-8629.20250700

https://zgywjj.magtechjournal.com/CN/Y2026/V23/I8/934

参考文献

[1] Sichuan Kelun Botai Biopharmaceutical Co., Ltd. Package Insert for Sacituzumab Tirumotecan for Injection[EB/OL]. (2025-10-10) [2025-10-20]. https://www.kelun-biotech.com/upload/2025-10-20/20141759568.
[2] Yin Y, Fan Y, Ouyang Q, et al.Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial[J]. Nat Med, 2025, 31(6): 1969-1975.
[3] Zhao S, Cheng Y, Wang Q, et al.Sacituzumab tirumotecan in advanced non-small-cell lung cancer with or without EGFR mutations: phase 1/2 and phase 2 trials[J]. Nat Med, 2025, 31(6): 1976-1986.
[4] Fang W, Li X, Wang Q, et al.Sacituzumab tirumotecan versus docetaxel for previously treated EGFR-mutated advanced non-small cell lung cancer: multicentre, open label, randomised controlled trial[J]. BMJ, 2025, 389: e085680.
[5] Ettorre V M, Palmieri L, Santin A D.Clinical pharmacologic considera-tions for antibody-drug conjugate in gynecologic cancers[J]. Expert Rev Clin Pharmacol, 2025, 18(7): 461-469.
[6] Chang H L, Schwettmann B, McArthur H L, et al. Antibody-drug conjugates in breast cancer: overcoming resistance and boosting immune response[J]. J Clin Invest, 2023, 133(18): e172156.
[7] Bignotti E, Ravaggi A, Romani C, et al.Trop-2 overexpression in poorly differentiated endometrial endometrioid carcinoma: implications for immunotherapy with hRS7, a humanized anti-Trop-2 monoclonal antibody[J]. Int J Gynecol Cancer, 2011, 21(9): 1613-1621.
[8] Kobayashi H, Minami Y, Anami Y, et al.Expression of the GA733 gene family and its relationship to prognosis in pulmonary adenocarcinoma[J]. Virchows Arch, 2010, 457(1): 69-76.
[9] Killock D.Sacituzumab tirumotecan improves OS in mTNBC[J]. Nat Rev Clin Oncol, 2025, 22(6): 382.
[10] Yin Q, Wu L, Han L, et al.Immune-related adverse events of immune checkpoint inhibitors: a review[J]. Front Immunol, 2023, 14: 1167975.
[11] Zhao Shidi, Ran Ran, Wang Quanfang, et al.Research progress of antibody-drug conjugate in treatment of breast cancer[J]. Chinese Journal of New Drugs and Clinical Remedies(中国新药与临床杂志), 2024, 43(3): 161-170.
[12] Nguyen T D, Bordeau B M, Balthasar J P.Mechanisms of ADC toxicity and strategies to increase ADC tolerability[J]. Cancers (Basel), 2023, 15(3): 713.
[13] Li X, Zhang L, Hu S, et al.Postmarketing safety of sacituzumab govitecan: a pharmacovigilance study based on the FDA adverse event reporting system[J]. Clin Pharmacol Ther, 2024, 115(2): 256-268.
[14] Mahalingaiah P K, Ciurlionis R, Durbin K R, et al.Potential mechanisms of target-independent uptake and toxicity of antibody-drug conjugates[J]. Pharmacol Ther, 2019, 200: 110-125.
[15] Zhao Shuang, Miao Qiuli, Song Yanqing, et al.Toripalimab-induced hypothyroidism: a case analysis[J]. Chinese Journal of Pharmacovigi-lance(中国药物警戒), 2021, 18(7): 697-699.
[16] Markides D M, Hita A G, Merlin J, et al.Antibody-drug conjugates: the toxicities and adverse effects that emergency physicians must know[J]. Ann Emerg Med, 2025, 85(3): 214-229.
[17] Krop I E, Kim S B, Martin A G, et al.Trastuzumab emtansine versus treatment of physician’s choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial[J]. Lancet Oncol, 2017, 18(6): 743-754.
[18] Yeh T Y, Luo I W, Hsieh Y L, et al.Peripheral neuropathic pain: from experimental models to potential therapeutic targets in dorsal root ganglion neurons[J]. Cells, 2020, 9(12): 2725.
[19] King G T, Eaton K D, Beagle B R, et al.A phase 1, dose-escalation study of PF-06664178, an anti-Trop-2/Aur0101 antibody-drug conjugate in patients with advanced or metastatic solid tumors[J]. Invest New Drugs, 2018, 36(5): 836-847
[20] Bardia A, Mayer I A, Vahdat L T, et al.Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer[J]. N Engl J Med, 2019, 380(8): 741-751.
[21] Modi S, Jacot W, Yamashita T, et al.Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer[J]. N Engl J Med, 2022, 387(1): 9-20.
[22] Liu Lianqi, Xiao Dian, Zhong Wu, et al.Related toxicities and research strategies of antibody-drug conjugates[J]. Chinese Journal of Pharma-covigilance(中国药物警戒), 2024, 21(7): 721-729.
[23] Bechtold-Peters K, Ruggiero A, Vriezen N, et al.CMC regulatory considerations for antibody-drug conjugates[J]. J Pharm Sci, 2023, 112(12): 2965-2980.
[24] Wang Yilu, Zhang Ke, Li Zhengxiang.Signal mining and analysis of adverse events of sacituzumab govitecan[J]. China Pharmacy(中国药房), 2024, 35(20): 2527-2532.

注射用芦康沙妥珠单抗致癌症患者急性疼痛2例分析

Two cases of acute systemic pain caused by sacituzumab tirumotecan for injection in cancer patients

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	吕欣鸽, 刘艾嘉, 武一, 潘晨, 王雨婷, 崔向丽. 免疫检查点抑制剂相关甲状腺功能障碍的多中心病例分析[J]. 中国药物警戒, 2026, 23(8): 892-897.
[2]	李剑屏, 杜宁, 唐敏, 周子原, 左靖. 691例新型抗肿瘤药品不良反应报告分析[J]. 中国药物警戒, 2026, 23(8): 904-908.
[3]	白丽琴, 聂红科, 杨淑婷, 蒋晓峰. 214例肌苷注射液不良反应报告分析[J]. 中国药物警戒, 2026, 23(8): 909-913.
[4]	张育茂, 刘君波, 罗千江, 谭槟滢, 邓彬, 邢惟青, 李玉珍. 口服复方聚乙二醇电解质散（Ⅱ）肠道准备致呕血2例分析[J]. 中国药物警戒, 2026, 23(8): 931-933.
[5]	谢华丽, 关碧茜, 卓羽波, 何洁丽, 陈喆. 注射用芦康沙妥珠单抗致序贯性超敏反应1例分析[J]. 中国药物警戒, 2026, 23(8): 938-940.
[6]	孙倩, 俞颖. 艾托格列净片联合聚乙二醇洛塞那肽注射液致血糖正常的糖尿病酮症酸中毒1例分析[J]. 中国药物警戒, 2026, 23(8): 941-943.
[7]	林利萍, 陈燕, 贾雪岭. 西格列他钠片致皮疹1例分析[J]. 中国药物警戒, 2026, 23(8): 944-947.
[8]	吴光华, 邢亚兵, 张胜男, 王菊平, 陈晓博, 夏旭东. 982例儿童皮肤药品不良反应分析[J]. 中国药物警戒, 2026, 23(7): 809-813.
[9]	刘丽娜, 张凤琴, 杨帆, 刘渊. 注射用哌拉西林钠他唑巴坦钠致抽搐伴呼吸困难1例分析[J]. 中国药物警戒, 2026, 23(7): 814-816.
[10]	钱霞, 郭志刚, 郑利光. 罗库溴铵注射液致气道痉挛1例分析[J]. 中国药物警戒, 2026, 23(7): 817-819.
[11]	杨亚静, 杨璐, 黄娜, 付裕豪, 沈颜红. 注射用两性霉素B胆固醇硫酸酯复合物致消化道出血1例分析[J]. 中国药物警戒, 2026, 23(7): 820-822.
[12]	靳小倩, 何志洁. 甲苯磺酸尼拉帕利胶囊致极重度血小板减少1例分析[J]. 中国药物警戒, 2026, 23(7): 823-825.
[13]	姜伟, 后开凤, 许磊, 丁丽, 许莹莹, 葛海林, 王君萍, 江洁美. 氟泽雷塞片致重度药物性肝损伤1例分析[J]. 中国药物警戒, 2026, 23(7): 826-828.
[14]	王春婷, 张瑞芳, 邓彬, 邹箴蕾, 王琨. 右旋糖酐铁注射液不良反应探析[J]. 中国药物警戒, 2026, 23(6): 672-676.
[15]	潘艳娟, 岳珂欣, 刘伟杰, 王领军, 王传升. 243例奥氮平不良反应报告分析[J]. 中国药物警戒, 2026, 23(6): 677-680.